Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Sell
45
NUTX Quote, Financials, Valuation and Earnings
Last price:
$109.97
Seasonality move
:
-16.6%
Day range:
$103.01 - $119.05
52-week range:
$4.16 - $152.51
Dividend yield:
0%
P/E ratio:
11.36x
P/S ratio:
1.17x
P/B ratio:
3.96x
Volume:
146.4K
Avg. volume:
122.5K
1-year change:
1574.01%
Market cap:
$579.4M
Revenue:
$479.9M
EPS (TTM):
-$10.79
Analysts' Opinion
-
Consensus RatingNutex Health has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $146.67, Nutex Health has an estimated upside of 39.94% from its current price of $104.81.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $100.00 representing 100% downside risk from its current price of $104.81.
Fair Value
-
According to the consensus of 2 analysts, Nutex Health has 39.94% upside to fair value with a price target of $146.67 per share.
NUTX vs. S&P 500
-
Over the past 5 trading days, Nutex Health has underperformed the S&P 500 by -29.19% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nutex Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nutex Health has grown year-over-year revenues for 7 quarters straight. In the most recent quarter Nutex Health reported revenues of $78.8M.
Earnings Growth
-
Nutex Health has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Nutex Health reported earnings per share of -$1.72.
Enterprise value:
631.8M
EV / Invested capital:
--
Price / LTM sales:
1.17x
EV / EBIT:
4.87x
EV / Revenue:
1.32x
PEG ratio (5yr expected):
--
EV / Free cash flow:
30.30x
Price / Operating cash flow:
26.93x
Enterprise value / EBITDA:
4.25x
Gross Profit (TTM):
$67.8M
Return On Assets:
-9.6%
Net Income Margin (TTM):
-14.09%
Return On Equity:
-48.3%
Return On Invested Capital:
-32.79%
Operating Margin:
12.8%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $219.3M | $247.6M | $479.9M | $69.7M | $257.6M | |
| Gross Profit | $15.4M | $34.8M | $196.3M | $13.2M | $141.6M | |
| Operating Income | -$4.6M | -$1.5M | $137.7M | $4.1M | $114.2M | |
| EBITDA | -$394M | -$14.6M | $148.7M | -$21.8M | $118.9M | |
| Diluted EPS | -$95.50 | -$10.74 | $9.23 | -$7.50 | $11.12 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $135.5M | $154M | $98M | $90.8M | $292.5M | |
| Total Assets | $308.6M | $394.7M | $431.8M | $398.2M | $655.3M | |
| Current Liabilities | $31.5M | $37.7M | $54.9M | $58.3M | $140.9M | |
| Total Liabilities | $161.2M | $203.1M | $311.4M | $319.1M | $453.4M | |
| Total Equity | $147.4M | $191.6M | $120.3M | $79.1M | $201.9M | |
| Total Debt | $100.5M | $89.1M | $38.2M | $40.5M | $40.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $50.6M | $1.3M | $23.2M | -$1.8M | $53.5K | |
| Cash From Investing | -$4.3M | -$11.2M | -$2.7M | $865.6K | -$395.3K | |
| Cash From Financing | -$48.1M | -$2.3M | $1.1M | -$3.9M | -$3M | |
| Free Cash Flow | $36M | -$8.2M | $20.8M | -$950.6K | -$341.8K | |
NUTX
Sector
Market Cap
$579.4M
$34.9M
Price % of 52-Week High
68.72%
44.35%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
1574.01%
-38.5%
Beta (5-Year)
0.269
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
-11.03%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$134.15
200-day SMA
Buy
Level
$39.56
Bollinger Bands (100)
Buy
Level
26.9 - 90.7
Chaikin Money Flow
Buy
Level
293.1K
20-day SMA
Sell
Level
$113.96
Relative Strength Index (RSI14)
Sell
Level
49.48
ADX Line
Buy
Level
42.97
Williams %R
Neutral
Level
-73.7135
50-day SMA
Buy
Level
$77.61
MACD (12, 26)
Buy
Level
16.04
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
2.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.1317)
Sell
CA Score
(Annual)
Level (-0.3877)
Sell
Beneish M-Score
(Annual)
Level (-0.7836)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-0.0343)
Buy
Piotroski F Score
(Annual)
Level (8)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.
Stock Forecast FAQ
In the current month, NUTX has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NUTX average analyst price target in the past 3 months is $146.67.
-
Where Will Nutex Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nutex Health share price will rise to $146.67 per share over the next 12 months.
-
What Do Analysts Say About Nutex Health?
Analysts are divided on their view about Nutex Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nutex Health is a Sell and believe this share price will drop from its current level to $100.00.
-
What Is Nutex Health's Price Target?
The price target for Nutex Health over the next 1-year time period is forecast to be $146.67 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NUTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nutex Health is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NUTX?
You can purchase shares of Nutex Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nutex Health shares.
-
What Is The Nutex Health Share Price Today?
Nutex Health was last trading at $109.97 per share. This represents the most recent stock quote for Nutex Health. Yesterday, Nutex Health closed at $104.81 per share.
-
How To Buy Nutex Health Stock Online?
In order to purchase Nutex Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 5.48% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 1.82% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 3.3% over the past day.
